US stock futures dip as Nvidia earnings spark little cheer
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a pharmaceutical company currently valued at $173 million, disclosed the outcomes of its 2025 Annual General Meeting of Shareholders (AGM) held on Thursday. According to InvestingPro data, the company maintains robust financial health with a current ratio of 8.02 and more cash than debt on its balance sheet. The company, headquartered in Minneapolis, Minnesota, and incorporated in British Columbia, Canada, saw the election of seven board members, the appointment of an independent registered public accounting firm, and the advisory approval of executive compensation.
The AGM, which took place with a 45.1% quorum of voting common shares, resulted in the re-election of all seven director nominees proposed by the board. The elected directors will serve until the next annual general meeting and until their successors are elected and qualified. Votes for the directors ranged from 6,651,961 to 6,749,002, with withheld votes between 204,156 and 295,394, and broker non-votes consistently at 12,396,835 for each director. The company’s stock has shown strong momentum, gaining 8.4% in the past week.
Additionally, shareholders approved the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposal received overwhelming support with 18,475,360 votes for and 868,830 withheld; there were no broker non-votes.
The executive compensation proposal received advisory approval with 6,536,608 votes for, 398,959 against, 11,788 abstentions, and 12,396,835 broker non-votes.
The company’s filing also included an exhibit related to the Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL.
This report is based on a press release statement and provides a summary of the key events and decisions made at DiaMedica Therapeutics’ 2025 AGM. InvestingPro analysis reveals that analysts have set price targets ranging from $6 to $11, with two analysts recently revising earnings expectations downward. Discover more detailed insights and 8 additional ProTips about DMAC in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, DiaMedica Therapeutics Inc. reported its first-quarter 2025 earnings, which exceeded analysts’ expectations. The company posted an earnings per share (EPS) of -0.18, beating the forecasted -0.20. Despite this positive earnings surprise, the company’s revenue remained at zero, consistent with forecasts. DiaMedica’s strong cash position, with total cash and investments of $37.3 million, provides a cash runway projected into the third quarter of 2026. Research and development expenses increased significantly to $5.7 million, reflecting the company’s commitment to advancing its clinical development programs. Analysts from Lake Street and H.C. Wainwright have shown interest in the progress of DiaMedica’s clinical trials, particularly in the preeclampsia and stroke treatment areas. The company is making strides in its preeclampsia program, with preliminary results expected between June and July 2025. DiaMedica plans to expand its study to U.S. and global markets, which could drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.